Jagsonpal Pharmaceuticals Limited — Q1 FY26 earnings call

Call held 31 Jul 2025

Management summary

Jagsonpal Pharma reported a strong Q1 FY26 with significant revenue and profit growth, driven by brand equity and operational discipline. Despite the termination of its CFO and pricing pressure on a key molecule, the company maintained robust margins and increased its cash balance, reinforcing its ability to pursue organic and inorganic growth strategies. Management reiterated its annual growth and margin expansion guidance, expecting improvements from Q2 onwards.

Highlights

  • Revenue increased by 23% YoY to ₹75.5 crores, driven by strong brand equity and focused marketing.

  • Gross margins expanded by 80 bps to 64.4%.

  • Operating EBITDA before ESOP grew 24% to ₹157 million, achieving margins of 20.8%.

  • PAT doubled to ₹108 million, reflecting a 560 bps improvement in net margins to 14.3%.

  • Cash balance increased by ₹153 million over the previous quarter, reaching ₹161 crores, strengthening operational scaling ability.

Concerns

  • The employment of the CFO was terminated due to acts of misbehavior, misconduct, and misrepresentation.

  • Pricing pressure on the Dydrogestorone molecule has led to a significant drop in sales from a peak of ₹40 crores to ₹10 crores.

  • Q1 EBITDA margin did not expand as guided due to higher marketing investments, though management expects improvement from Q2.

Key financials

  1. Revenue ₹75.5 Cr +23%YoY
  2. Gross Margins 64.4%
  3. Operating EBITDA (pre-ESOP) ₹15.7 Cr +24%YoY
  4. Operating EBITDA Margin 20.8%
  5. PAT ₹10.8 Cr +100%YoY
  6. Net Margins 14.3%
  7. Cash Balance ₹161 Cr
  8. Yash Pharma Revenue Contribution ₹12 Cr
  9. ESOP Cost ₹1.5 Cr

What they filed

Q1 FY27: revenue up 7.9%, net profit up 18.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue75 74 59 76 74 −1%73 −1%64 +8%82 +8%
EBITDA16 16 9 14 16 +0%16 +0%11 +22%17 +21%
Net profit11 32 7 11 13 +18%11 −66%9 +29%13 +18%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • M&A Yash Pharma business Acquisition · Integrated · Consideration ₹[object Object] (undisclosed)

    Part of inorganic growth strategy

    Contributed ₹12 crores to topline this quarter, up from ₹3.5 crores last year. Operating margins of 12.5% at acquisition, now closer to corporate margins.

    Yes. So, if you notice, we did our first inorganic about 12 months back when almost Rs. 90 plus crores got used in that inorganic of acquiring Yash Pharma business. We came to conclude another transaction in the early part of this year, which we had to call off at the last minute because of certain developments around the condition precedence, which could not be fulfilled. So, fundamentally, we have a clear inorganic strategy in mind, but it has to meet both strategy and pricing. So, we have no pressure to use it. Having said that, this entire money, if it will be used, will be only for inorganic strategy, else it will be returned to the shareholders in an appropriate form.
  • M&A Undisclosed Acquisition · Abandoned

    Could not fulfill condition precedence due to certain developments

    We came to conclude another transaction in the early part of this year, which we had to call off at the last minute because of certain developments around the condition precedence, which could not be fulfilled.
  • Liquidity Cash ₹161 Cr Company ended the quarter with a closing balance of almost Rs. 161 crores, an increase of Rs. 153 million over the previous quarter. It also generates about Rs. 5 crores cash monthly.
    We ended the quarter with a closing balance of almost Rs. 161 crores or Rs. 1,609 million, an increase of Rs. 153 million over the previous quarter. This strengthens our ability to scale operations efficiently while reinforcing confidence in meeting annual guidance supported by both organic and inorganic growth initiatives.

Guidance & targets

Profitability

  • ROE Profitability · next 2 years · High confidence 18-19%
    Certainly, all our efforts are in that regard, and I don't see any reason why that should be disturbed.

    — Manish Gupta

  • EBITDA Margin Expansion Profitability · FY26 · High confidence 100-150 bps
    Yes. So, I think we will still end up with a 100-150 bps margin improvement which we have guided to. Q1 certainly had certain buildup of cost as we invested significantly more in marketing and that is what if you see our other expenses are higher than normal in this quarter and that is what has kind of compromised on our margin expansion in this quarter. So, I do believe that will start showing up from Q2 onwards.

    — Manish Gupta

Growth

  • Overall Growth Growth · FY26 · High confidence 15%
    So, therefore, we still stick to overall guidance of 15% for the year. Pharma industry, as we are all aware, is not growing as fast as it used to in the past. So, I think we are not upping our guidance. We are sticking to our 15% guidance for the year on a current status quo basis. This number, of course, can change should there be any inorganic strategy during the year.

    — Manish Gupta

  • Organic Growth Growth · forward-looking · High confidence 12-14%
    If you see for way forward, we are targeting or we are guiding to 12%-14% organic growth.

    — Manish Gupta

Productivity

  • MR Productivity Productivity · eventually · Medium confidence ₹3-3.5 lakhs per month
    As far as targets are concerned, I think eventually we look to aim above Rs. 3-Rs. 3.5 lakhs.

    — Manish Gupta

Cost

  • ESOP Cost Cost · from Q3 onwards · High confidence ₹1.1-1.2 million

    Previously ₹15-16 million → ₹1.1-1.2 million

    So, I believe the ESOP cost for this quarter was 15 million. It should stay between 15 and 16 million in Q2 and Q3 onwards it will start coming down. It will get closer to 12 million is my guess simply because if you recollect, we had given a major part of these ESOPs 2 years back in September 23 or September 22 was the major ESOP thing. So, therefore, we are now getting into the last tranche in a way from September onwards. So, you will see a dip in the ESOP cost from Q3 onwards to about 1.1-1.2 million.

    — Manish Gupta

What to watch in Q2 FY26

EBITDA Margin Expansion

next quarter
Current No expansion in Q1 FY26
Target Improvement from Q2 FY26 onwards, contributing to 100-150 bps annual expansion

Why it matters

This is a key profitability target, and Q1 performance was below expectation due to marketing investments. Verification in Q2 will confirm if the strategy is yielding results.

So, I do believe that will start showing up from Q2 onwards.

Risks & concerns

  • CFO misconduct and termination

    high

    The company terminated its CFO's employment due to misbehavior, misconduct, and misrepresentation, indicating a serious internal governance issue.

    Management acknowledged

  • Pricing pressure on Dydrogestorone molecule

    medium

    The Dydrogestorone molecule, once a significant contributor, has seen sales drop from ₹40 crores to ₹10 crores due to pricing pressure, as the company refuses to compromise on its pricing strategy, leading to a loss of market share.

    Management acknowledged

  • Intensely competitive Indian pharma market

    medium

    The Indian market is intensely competitive, making it challenging to gain market share, although the company's focus on niche molecules helps mitigate some direct competition.

    Management acknowledged

  • Field force attrition

    low

    Field force attrition is an industry-wide problem, which the company is addressing through skilling, better retention, training, and incentive structures.

    Management acknowledged

Q&A highlights

8 direct
Field force scaling and optimization for growth Direct
So, technically, we are not making any changes. Of course, there is some element of optimization as we reorient the field force for more performance. So, there is a small optimization happening in terms of changing geographies and what not. But having said that, overall, our focus is on improvement of their productivity rather than any large-scale changes in terms of both numbers and anything around the field force.

Clarifies management's strategy for field force, emphasizing productivity and optimization over headcount growth.

Asked by Deepesh J. Sancheti

Maintaining market share and mitigating pricing pressure Direct
So, typically, in the nature of business that we are in, and if you understand our business model, we are in smaller niche molecules rather than over-competitive molecules. So, the pricing pressure in that sense is limited. ... Other than that, we do not see pricing pressure set up.

Explains the company's strategy of focusing on niche molecules to avoid intense pricing pressure, with Dydrogestorone being an exception.

Asked by Deepesh J. Sancheti

Criteria and timelines for inorganic acquisitions given cash balance Direct
So, fundamentally, we have a clear inorganic strategy in mind, but it has to meet both strategy and pricing. So, we have no pressure to use it. Having said that, this entire money, if it will be used, will be only for inorganic strategy, else it will be returned to the shareholders in an appropriate form.

Highlights the company's disciplined approach to M&A, prioritizing strategic fit and pricing over simply deploying cash, with a commitment to shareholder returns if no suitable opportunities arise.

Asked by Amit Agicha

M&A target therapy areas or geographies Direct
Fundamentally, our focus is clearly on India and we do not wish to go anywhere outside of India. And within the therapeutic presence, generally, we are in subchronic therapies and we intend to stay that way, generally speaking.

Provides clear strategic boundaries for M&A, focusing on the Indian market and subchronic therapeutic segments.

Asked by Amit Agicha

Ensuring quality benchmarks with third-party manufacturers Direct
So, in that sense, a fair bit of our manufacturing is under our direct control and not indirect control. Having said that, as I said, this entire operation is undertaken under our quality management system. We have people positioned in some of our contract manufacturers who oversee quality.

Addresses concerns about quality control given reliance on third-party manufacturers, detailing the company's robust quality management system and direct oversight.

Asked by Pratik Bafna

Drivers of Q1 growth and update on annual guidance Direct
So, last year, Q1 had Yash Pharma business only for one month as against 3 months this year. So, part of this growth has come because of that. Between 9%-10% is our organic growth and about rest of the growth has come from the annualization or the full quarter benefit of Yash Pharma business. So, therefore, we still stick to overall guidance of 15% for the year.

Clarifies the contribution of the Yash Pharma acquisition to Q1 growth and confirms the company's commitment to its 15% annual growth guidance.

Asked by Dhruv Maheshwari

EBITDA margin expansion guidance and Q1 performance Direct
Q1 certainly had certain buildup of cost as we invested significantly more in marketing and that is what if you see our other expenses are higher than normal in this quarter and that is what has kind of compromised on our margin expansion in this quarter. So, I do believe that will start showing up from Q2 onwards.

Explains the reason for no margin expansion in Q1 and reiterates confidence in achieving the annual 100-150 bps EBITDA margin improvement from Q2.

Asked by Dhruv Maheshwari

MySakhi initiative alignment with company's brand/marketing strategy Direct
MySakhi has two components to it or more than two, but two are priority ones. One is constructing physical amenities for women or girls students in schools and colleges where no such amenities exist at this point of time. ... The second part of this program is the education part, wherein we are using MySakhi.in as an instrument. It is a website which is dedicated towards women education.

Provides a detailed explanation of the company's CSR initiative, MySakhi, highlighting its focus on women's health and education, aligning with the company's values.

Asked by Amit Agicha

2 min read 7 chapters

Detailed narrative

Strong Q1 FY26 Performance Driven by Brand Equity

Jagsonpal Pharma commenced FY26 on a robust note, reporting a 23% year-on-year revenue growth to ₹75.5 crores. This growth was primarily attributed to strong brand equity and a focused marketing push. The company achieved an 80 bps expansion in gross margins, reaching 64.4%, and saw its Operating EBITDA before ESOP increase by 24% to ₹157 million, with margins at 20.8%. Net profit doubled to ₹108 million, reflecting a 560 bps improvement in net margins to 14.3%.

CFO Termination and Governance Commitment

The company disclosed the termination of its CFO, Mr. Sachin Jain, on July 8, 2025, within his probation period. The termination was due to acts of misbehavior, misconduct, and misrepresentation. Management emphasized its commitment to ethics and governance, stating that the Board of Directors acted quickly and decisively to safeguard the company's values.

Disciplined Inorganic Growth Strategy and Strong Liquidity

Jagsonpal Pharma ended the quarter with a healthy cash balance of ₹161 crores, an increase of ₹153 million from the previous quarter, and generates approximately ₹5 crores in cash monthly. The company's inorganic growth strategy is focused on India and subchronic therapeutic segments, open to both brand and business acquisitions. Management stated there is no pressure to deploy cash, prioritizing strategic fit and pricing, and indicated that funds not used for M&A would be returned to shareholders.

Field Force Optimization and Productivity Focus

The company is focusing on 'skilling up' its field force rather than merely increasing headcount, aiming to improve productivity. MR productivity has already seen a 10% improvement, with a long-term target of ₹3-3.5 lakhs per month. Initiatives include better retention, training, and incentive structures, acknowledging field force attrition as an industry-wide challenge.

Dydrogestorone Pricing Pressure and Market Share Strategy

Jagsonpal Pharma acknowledged significant pricing pressure on its Dydrogestorone molecule, which has seen sales decline from a peak of ₹40 crores to ₹10 crores. The company maintains its pricing strategy, even if it means losing market share in this specific molecule, as it prioritizes quality and ethics over aggressive competition in certain segments.

FY26 Guidance Maintained Despite Q1 Margin Impact

The company reiterated its full-year guidance of 15% overall growth and 100-150 bps EBITDA margin expansion. While Q1 did not show margin expansion due to higher marketing investments, management expects improvements from Q2 onwards. Organic growth for Q1 was 9-10%, with a forward-looking organic growth target of 12-14%.

MySakhi CSR Initiative for Women's Health and Education

Jagsonpal Pharma detailed its MySakhi CSR initiative, which focuses on women's health and education. The program includes constructing physical amenities like toilets and sanitary pad dispensing machines in schools and colleges, and an educational platform (MySakhi.in) offering webinars and resources on women's health topics, including menstrual hygiene and menopause.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls